Screener
CorMedix CRMD D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: CorMedix’s 10-Q, filed May 14, 2026. Open the filing →
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
FAQ
- What is CorMedix's D&A?
- CorMedix (CRMD) reported D&A of $10.54M in Q1 2026.
- How has CorMedix's D&A changed year-over-year?
- CorMedix's D&A increased by 20197.2% year-over-year, from $51.95K to $10.54M.
- What is the long-term trend for CorMedix's D&A?
- Over 4 years (2021 to 2025), CorMedix's D&A has grown at a 286.7% compound annual growth rate (CAGR), from $61.89K to $13.84M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about CorMedix's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude